Pacira BioSciences' Other Operating Expenses fell 77.54% to $48.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.6 million, marking a year-over-year decrease of 48.48%. This contributed to the annual value of $391.0 million for FY2024, which is 61.58% up from last year.
Per Pacira BioSciences' latest filing, its Other Operating Expenses stood at $48.6 million for Q3 2025, which was down 11.94% from $55.2 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Other Operating Expenses ranged from a high of $216.4 million in Q3 2024 and a low of $35.2 million during Q1 2021.
Its 3-year average for Other Operating Expenses is $71.5 million, with a median of $57.2 million in 2023.
As far as peak fluctuations go, Pacira BioSciences' Other Operating Expenses skyrocketed by 278.19% in 2024, and later crashed by 77.54% in 2025.
Pacira BioSciences' Other Operating Expenses (Quarterly) stood at $87.3 million in 2021, then climbed by 2.47% to $89.5 million in 2022, then declined by 28.16% to $64.3 million in 2023, then dropped by 15.66% to $54.2 million in 2024, then plummeted by 77.54% to $48.6 million in 2025.
Its Other Operating Expenses stands at $48.6 million for Q3 2025, versus $55.2 million for Q2 2025 and $48.6 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value